Mar 10 2010
Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the implementation of a new biostatistics infrastructure that will significantly enhance the analysis and delivery of quality clinical trial data for customers. The centralized SAS®-based platform provides a virtual environment allowing for simultaneous access and analysis of clinical trial data by Kendle's global Biostatistics and Scientific Programming teams from anywhere in the world, creating significant time savings and further enhancing data security. The launch of the new system will be seamless to customers.
"With this new environment data will be processed at the server level much faster than ever before, greatly improving the productivity of our teams around the world and expediting the delivery of quality data to our customers," said John A. Whitaker, Ph.D., Vice President, Biostatistics and Statistical Programming. "This investment allows Kendle to provide a more globally integrated solution to meet our customers' needs anywhere, any time."
In addition to improved efficiency, quality and security, the centralized platform also positions Kendle to better leverage its growing operations in India. Other benefits of the new infrastructure implementation include improved network performance and bandwidth availability; reduced licensing requirements; and simplification of the testing, production and recovery environments.
Kendle's Biostatistics and Scientific Programming team is comprised of a worldwide network of experts utilizing globally consistent processes to maximize operating efficiencies and ensure delivery of the highest quality data analysis and reporting to our customers. The team specializes in the planning and execution of meaningful analyses of even the most complex clinical trials. Kendle is equipped to provide actionable data as either a functional service or full service provider, and is currently involved in statistical services worldwide.
Source:
Kendle International Inc.